Page last updated: 2024-12-08

moronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

moronic acid: from root bark extract of Ozoroa mucronata; RN & N1 from 9th CI [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

moronic acid : A pentacyclic triterpenoid that is olean-18-ene substituted at position 3 by an oxo group and position 28 by a carboxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Ozoroagenus[no description available]AnacardiaceaeThe sumac plant family in the order Sapindales, subclass Rosidae, class Magnoliopsida. They are tropical and subtropical trees, shrubs, and woody vines that have resin ducts in the bark. The sap of many of the species is irritating to the skin.[MeSH]

Cross-References

ID SourceID
PubMed CID489941
CHEMBL ID472646
CHEBI ID30815
SCHEMBL ID324972
MeSH IDM0081033

Synonyms (33)

Synonym
3-oxoolean-18-en-28-oic acid
(4as,6ar,6br,8ar,12ar,12br,14as)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-icosahydropicene-4a-carboxylic acid
CHEBI:30815 ,
(4as,6ar,6br,8ar,12ar,12br,14as)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-octadecahydro-2h-picene-4a-carboxylic acid
6713-27-5
moronic acid
(4as,6ar,6ar,6br,8ar,12ar,14as)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxo-4,5,6,6a,7,8,8a,11,12,13,14,14a-dodecahydro-3h-picene-4a-carboxylic acid
smr000232278
MLS000563430 ,
MLS000728508
moronicacid
CHEMBL472646
LMPR0106150002
NCGC00247448-02
NCGC00247448-01
xw8w7hc4jk ,
unii-xw8w7hc4jk
SCHEMBL324972
(4as,6ar,6ar,6br,8ar,12ar,14as)-2,2,6a,6b,9,9,12a-heptamethyl-10-oxidanylidene-4,5,6,6a,7,8,8a,11,12,13,14,14a-dodecahydro-3h-picene-4a-carboxylic acid
cid_489941
(4as,6ar,6ar,6br,8ar,12ar,14as)-10-keto-2,2,6a,6b,9,9,12a-heptamethyl-4,5,6,6a,7,8,8a,11,12,13,14,14a-dodecahydro-3h-picene-4a-carboxylic acid
bdbm54263
M2610
AKOS032948476
DTXSID30891948
FS-8943
mfcd11113464
Q6913266
(+)-moronic acid
ambronic acid
olean-18-en-28-oic acid, 3-oxo-
HY-N3242
CS-0023704

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
anti-HSV-1 agentAn anti-HSV agent agent that destroys or inhibits the replication of herpes simplex virus-1.
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pentacyclic triterpenoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
ATAD5 protein, partialHomo sapiens (human)Potency18.35640.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency6.68650.000811.382244.6684AID686978; AID686979
67.9K proteinVaccinia virusPotency10.61010.00018.4406100.0000AID720579; AID720580
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.63100.707936.904389.1251AID504333
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency44.66843.548119.542744.6684AID743266
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency33.58750.168316.404067.0158AID720504
survival motor neuron protein isoform dHomo sapiens (human)Potency5.01190.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency0.01120.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency10.00000.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
tumor necrosis factorHomo sapiens (human)IC50 (µMol)10.88000.07935.809814.7275AID2485
nucleotide-binding oligomerization domain-containing protein 2 isoform 1Homo sapiens (human)IC50 (µMol)8.07701.14607.137219.7000AID2001
Receptor-type tyrosine-protein phosphatase FHomo sapiens (human)IC50 (µMol)45.60001.30002.66604.2300AID687543
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)13.20000.00053.49849.7600AID1291099; AID687539
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Ki8.00000.19004.83279.6000AID687544
Low molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)IC50 (µMol)24.00002.86009.633617.2000AID687540; AID687541
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nucleotide-binding oligomerization domain-containing protein 1 isoform 1Homo sapiens (human)EC50 (µMol)2.27000.17007.258418.7000AID1578
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
cell adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell surface receptor protein tyrosine phosphatase signaling pathwayReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell migrationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projection regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
regulation of axon regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
synaptic membrane adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
negative regulation of receptor bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
heparin bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
chondroitin sulfate proteoglycan bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell adhesion molecule bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
acid phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projectionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuronal cell bodyReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytosolLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytoplasmic side of plasma membraneLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
sarcolemmaLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular exosomeLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID492523Therapeutic index, ratio of IC50 for human H9 cells to EC50 for HIV 3B2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID1291099Inhibition of recombinant human PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives.
AID687539Inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID402596Cytotoxicity against human A2780 cells2004Journal of natural products, Jun, Volume: 67, Issue:6
Cytotoxic triterpenoids from Acridocarpus vivy from the Madagascar rain forest.
AID357960Cytotoxicity against human H9 cells2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
AID687538Inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate at 10 to 50 uM after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687542Inhibition of yeast LMW-PTP1 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687534Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 3 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687544Mixed type inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID279274Antibacterial activity against Helicobacter pylori after 48 hrs2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori.
AID687540Inhibition of human recombinant LMW-PTP1 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687535Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 5 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID357961Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
AID687533Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 1 hr by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID399882Antiviral activity against HIV2004Journal of natural products, Feb, Volume: 67, Issue:2
Current developments in the discovery and design of new drug candidates from plant natural product leads.
AID492522Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID687536Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 7 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID357962Therapeutic index, ratio of IC50 for human H9 cells to EC50 of HIV1 3B2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
AID687541Inhibition of human recombinant LMW-PTP2 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687543Inhibition of human recombinant LAR expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.55)18.7374
1990's1 (4.55)18.2507
2000's7 (31.82)29.6817
2010's10 (45.45)24.3611
2020's3 (13.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.64 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (91.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]